Early Detection Of Insulin Resistance In Patients With Paranoid Schizophrenia Receiving Antipsychotic Therapy

I. Romash SHEE «Ivano-Frankivsk National Medical University»

Abstract

The article deals with the problem of insulin resistance, which is today considered a key aspect of the metabolic syndrome. The aim of our study was to investigate the effect of therapy classical and atypical neuroleptics on indicators of insulin resistance in patients with paranoid schizophrenia. During the study ,we found, that taking atypical neuroleptics for a long period, promotes infringement of carbohydrate metabolism. This reflected significant growth of blood glucose, immunoreactive insulin, postprandial glycemia, index NOMA-IR that are informative for the verification of an abnormal carbohydrate metabolism, insulin resistance and detection of type II diabetes in patients with paranoid schizophrenia who protractedly taking antipsychotics.

Downloads

Download data is not yet available.

References

Burchinskiy S. G. Problema vybora atipichnogo neyroleptika: kliniko-psikhofarmakologicheskie aspekty [The problem of selecting an atypical neuro-leptic: clinical and psychopharmacological aspects]. Ukrai’ns’kyj visnyk psyhonevrologii’, 2012, vol. 20, is-sue 4 (73), pp. 79-83. (In Russ.)

Alberti K. G., Zimmet P. Shaw J. International Dia betes Federation: a consensus on Type 2 diabetes prevention. Diabet. Med., 2007, vol. 24 (5), pp. 451-463.

International Diabetes Federation. The IDF con-sensus worldwide definition of the metabolic syndrome (article online), 2005. Available at: http:// www/idf.jrg/webdata/docs/metac syndrome-def.pdf.

Standarts of Medical Care in Diabetes-2011, American Diabetes Association. Diabetes Care, 2011, vol. 34, suppl. 1, pp. 11-61.

Nakaz MOZ Ukrai’ny No 1118 vid 21.12.2012. «Pro zatverdzhennja ta vprovadzhennja medyko-teh-nologichnyh dokumentiv zi standartyzacii’ medychnoi’ dopomogy pry CD 2 typu» [MOH Ukraine number 1118 of 21. 12. 2012 «On approval and introduction of medical and technological documents for standardization of medical care in type 2 diabetes»]. (In Ukr.)

Pionova O. M. Postprandial’na glikemija ta apoprotei’nemija u hvoryh na arterial’nu gipertenziju z suputnim ozhyrinnjam [Postprandial glycemia and apoproteyinemiya in patients with hypertension with concomitant obesity]. Aktual’nye problemy transportnoy meditsiny, 2014, vol. 2 (36-ІІ), pp. 75-80. (In Ukr.)

Vaceba T. S. Vzajemozv’jazok mizh dyslipi-demijeju ta insulinorezystentnistju u hvoryh na pervyn-nyj gipotyreoz [The relationship between dyslipidemia and insulin resistance in patients with primary hypothyroidism]. Klinichna ta eksperymental’na pa-tologija, 2013, vol. ХІІ, no. 2(44), pp. 42-45. (In Ukr.)

Perceva T. O., Maljar K. Ju. Dynamika pokaznykiv insulinorezystentnosti zalezhno vid vydu cukroznyzhuval’noi’ terapij u hvoryh iz vpershe vyjavlenym cukrovym diabetom 2-go typu [The evolution of insulin resistance, depending on the type of hypoglycemic therapies in patients with newly diagnosed diabetes mellitus type 2]. Klinichna endokrynologija ta endokrynna hirurgija, 2010, no. 1 (30), pp. 23-27. (In Ukr.)

Lakka H. M., Laaksonen D. E. The metabolic syndrome and total cardiovascular disease mortality in middle-aged man, JAMA, 2002, vol. 288, p. 2709-2716.